Drugs / HH-120
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05753878 | Nov 2022 → Jan 2023 | COVID-19 | Huahui Health | Completed | No outcome recorded |
| Phase 1 | NCT05116865 | Nov 2021 → May 2022 | COVID-19 | Huahui Health | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05713318 | Jan → Jun 2023 | COVID-19 | Huahui Health | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05765279 | Oct → Dec 2022 | COVID-19 | Beijing Ditan Hospital | Completed | No outcome recorded |
| — | NCT05659602 | Jul 2022 → Jan 2023 | COVID-19 | Beijing Ditan Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06039163 Comparator | Apr → Oct 2022 | COVID-19 | Huahui Health | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HH-120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05116865 ↗ |
| Modality | Protein / enzyme biologic | “HH-120 is a novel inhalable biologic” NCT05116865 ↗ |
| Route | Inhaled | “HH-120 administered by aerosol inhalation” NCT05116865 ↗ |